Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 64, Issue 4, 2016, Pages 908-915

  Junker, Anders E ^a,b   Gluud, Lise L ^a   Van Hall, Gerrit ^a   Holst, Jens J ^b   Knop, Filip K ^a,b   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endogenous glucose production; Energy metabolism; Glucagon; Glucagon like peptide 1 (GLP 1); Lipolysis; Non alcoholic fatty liver disease (NAFLD)

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; PLACEBO; STABLE ISOTOPE; GLUCAGON; GLUCOSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY METABOLISM; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLUCAGONEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LIPOLYSIS; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; POSTPRANDIAL STATE; PRIORITY JOURNAL; RESPIRATORY QUOTIENT; SINGLE BLIND PROCEDURE; AGED; BIOSYNTHESIS; LIVER; METABOLISM; MIDDLE AGED; SECRETION (PROCESS);

ADULT; AGED; ENERGY METABOLISM; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; LIPOLYSIS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84955593210     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.014     Document Type: Article

References (47)

1. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42 2005 44 52
2. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, and A.J. McCullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
3. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, and et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Diabetes 50 2001 1844 1850
4. G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, and et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 2007 1212 1218
5. K.J. Hare, T. Vilsbøll, J.J. Holst, and F.K. Knop Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes Am J Physiol Endocrinol Metab 298 2010 E832 E837
6. A.D. Baron, L. Schaeffer, P. Shragg, and O.G. Kolterman Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics Diabetes 36 1987 274 283
7. C. Bernsmeier, A.C. Meyer-Gerspach, L.S. Blaser, L. Jeker, R.E. Steinert, M.H. Heim, and et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic Fatty liver disease PLoS One 9 2014 e87488
8. S.L. Conarello, G. Jiang, J. Mu, Z. Li, J. Woods, E. Zycband, and et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia Diabetologia 50 2007 142 150
9. K.M. Habegger, K.M. Heppner, N. Geary, T.J. Bartness, R. DiMarchi, and M.H. Tschöp The metabolic actions of glucagon revisited Nat Rev Endocrinol 6 2010 689 697
10. K.J. Hare, T. Vilsbøll, M. Asmar, C.F. Deacon, F.K. Knop, and J.J. Holst The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action Diabetes 59 2010 1765 1770
11. T. Vilsbøll, T. Krarup, S. Madsbad, and J.J. Holst Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects Regul Pept 114 2003 115 121
12. J.J. Holst, F.K. Knop, T. Vilsbøll, T. Krarup, and S. Madsbad Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 2011 S251 S257
13. K.J. Hare, F.K. Knop, M. Asmar, S. Madsbad, C.F. Deacon, J.J. Holst, and et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus J Clin Endocrinol Metab 94 2009 4679 4687
14. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W. Cummings, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
15. M.B. Christensen, S. Calanna, J.J. Holst, T. Vilsbøll, and F.K. Knop Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes J Clin Endocrinol Metab 99 2014 E418 E426
16. W. Bablok, H. Passing, R. Bender, and B. Schneider A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III J Clin Chem Clin Biochem 26 1988 783 790
17. C. Orskov, J. Jeppesen, S. Madsbad, and J.J. Holst Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine J Clin Invest 87 1991 415 423
18. C. Orskov, L. Rabenhøj, A. Wettergren, H. Kofod, and J.J. Holst Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans Diabetes 43 1994 535 539
19. E. Wolsk, H. Mygind, T.S. Grøndahl, B.K. Pedersen, and G. van Hall IL-6 selectively stimulates fat metabolism in human skeletal muscle Am J Physiol Endocrinol Metab 299 2010 E832 E840
20. R. Steele, J.S. Wall, R.C. De Bodo, and N. Altszuler Measurement of size and turnover rate of body glucose pool by the isotope dilution method Am J Physiol 187 1956 15 24
21. J.A. Romijn, E.F. Coyle, L.S. Sidossis, A. Gastaldelli, J.F. Horowitz, E. Endert, and et al. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration Am J Physiol 265 1993 E380 E391
22. E. Ferrannini The theoretical bases of indirect calorimetry: a review Metab Clin Exp 37 1988 287 301
23. E. Van Cauter, F. Mestrez, J. Sturis, and K.S. Polonsky Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance Diabetes 41 1992 368 377
24. F. Bril, R. Lomonaco, B. Orsak, C. Ortiz-Lopez, A. Webb, F. Tio, and et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis Hepatology 59 2014 2178 2187
25. B.E. Dunning, M.C. Moore, T. Ikeda, D.W. Neal, M.F. Scott, and A.D. Cherrington Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs Metab Clin Exp 51 2002 1324 1330
26. K. Cusi Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 142 2012 e6 10.1053/j.gastro.2012.02.003
27. E. Fabbrini, D. deHaseth, S. Deivanayagam, B.S. Mohammed, B.E. Vitola, and S. Klein Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content Obesity (Silver Spring) 17 2009 25 29 10.1038/oby.2008.494
28. R. Lomonaco, C. Ortiz-Lopez, B. Orsak, A. Webb, J. Hardies, C. Darland, and et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease Hepatology 55 2012 1389 1397
29. F.K. Knop, K. Aaboe, T. Vilsbøll, A. Vølund, J.J. Holst, T. Krarup, and et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity Diabetes Obes Metab 14 2012 500 510
30. E. Ferrannini, E. Muscelli, A. Natali, R. Gabriel, A. Mitrakou, A. Flyvbjerg, and et al. Association of fasting glucagon and proinsulin concentrations with insulin resistance Diabetologia 50 2007 2342 2347
31. T. Kawaguchi, E. Taniguchi, M. Itou, M. Sakata, S. Sumie, and M. Sata Insulin resistance and chronic liver disease World J Hepatol 3 2011 99 107 10.4254/wjh.v3.i5.99
32. W. Nolte Metabolic disturbances in liver cirrhosis: hepatogenous diabetes Dtsch Med Wochenschr 135 2010 716 [Author reply 716]
33. A. Charbonneau, K. Couturier, M.-S. Gauthier, and J.-M. Lavoie Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training Int J Sports Med 26 2005 432 441
34. A. Charbonneau, C.G. Unson, and J.-M. Lavoie High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise J Physiol (Lond) 579 2007 255 267
35. Y. Liang, M.C. Osborne, B.P. Monia, S. Bhanot, W.A. Gaarde, C. Reed, and et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice Diabetes 53 2004 410 417
36. C.F. Deacon, M. Kelstrup, R. Trebbien, L. Klarskov, M. Olesen, and J.J. Holst Differential regional metabolism of glucagon in anesthetized pigs Am J Physiol Endocrinol Metab 285 2003 E552 E560
37. C. Longuet, A.M. Robledo, E.D. Dean, C. Dai, S. Ali, I. McGuinness, and et al. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor Diabetes 62 2013 1196 1205
38. A. Perea, F. Clemente, J. Martinell, M.L. Villanueva-Peñacarrillo, and I. Valverde Physiological effect of glucagon in human isolated adipocytes Horm Metab Res 27 1995 372 375
39. H. Ishihara, P. Maechler, A. Gjinovci, P.-L. Herrera, and C.B. Wollheim Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells Nat Cell Biol 5 2003 330 335
40. W.O. Creutzfeldt, N. Kleine, B. Willms, C. Orskov, J.J. Holst, and M.A. Nauck Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients Diabetes Care 19 1996 580 586
41. J. De Heer, C. Rasmussen, D.H. Coy, and J.J. Holst Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas Diabetologia 51 2008 2263 2270
42. J.J. Holst, C.F. Deacon, T. Vilsbøll, T. Krarup, and S. Madsbad Glucagon-like peptide-1, glucose homeostasis and diabetes Trends Mol Med 14 2008 161 168
43. M. Seghieri, E. Rebelos, A. Gastaldelli, B.D. Astiarraga, A. Casolaro, E. Barsotti, and et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 56 2013 156 161
44. S. Lee, M. Rivera-Vega, H.M.A.A. Alsayed, C. Boesch, and I. Libman Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease Pediatr Diabetes 16 2015 211 218
45. J.P. Felber, E. Ferrannini, A. Golay, H.U. Meyer, D. Theibaud, B. Curchod, and et al. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes Diabetes 36 1987 1341 1350
46. N. Pannacciulli, J.C. Bunt, J. Koska, C. Bogardus, and J. Krakoff Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans Am J Clin Nutr 84 2006 556 560
47. A. Kotronen, A. Seppälä-Lindroos, S. Vehkavaara, R. Bergholm, K.N. Frayn, B.A. Fielding, and et al. Liver fat and lipid oxidation in humans Liver Int 29 2009 1439 1446 10.1111/j.1478-3231.2009.02076.x